237 related articles for article (PubMed ID: 27475804)
1. Immunotherapy as a Potential Treatment for Chordoma: a Review.
Patel SS; Schwab JH
Curr Oncol Rep; 2016 Sep; 18(9):55. PubMed ID: 27475804
[TBL] [Abstract][Full Text] [Related]
2. Expression of programmed cell death ligand 1 (PD-L1) and prevalence of tumor-infiltrating lymphocytes (TILs) in chordoma.
Feng Y; Shen J; Gao Y; Liao Y; Cote G; Choy E; Chebib I; Mankin H; Hornicek F; Duan Z
Oncotarget; 2015 May; 6(13):11139-49. PubMed ID: 25871477
[TBL] [Abstract][Full Text] [Related]
3. Outcomes following attempted en bloc resection of cervical chordomas in the C-1 and C-2 region versus the subaxial region: a multiinstitutional experience.
Molina CA; Ames CP; Chou D; Rhines LD; Hsieh PC; Zadnik PL; Wolinsky JP; Gokaslan ZL; Sciubba DM
J Neurosurg Spine; 2014 Sep; 21(3):348-56. PubMed ID: 24926926
[TBL] [Abstract][Full Text] [Related]
4. Chordoma dedifferentiation after proton beam therapy: a case report and review of the literature.
Frankl J; Grotepas C; Stea B; Lemole GM; Chiu A; Khan R
J Med Case Rep; 2016 Oct; 10(1):280. PubMed ID: 27729085
[TBL] [Abstract][Full Text] [Related]
5. Recurrent chordoma of the L2 vertebra: a case report.
Heylen S; Michielsen J; Mahieu G; Somville J
Acta Orthop Belg; 2010 Jun; 76(3):416-9. PubMed ID: 20698468
[TBL] [Abstract][Full Text] [Related]
6. Combinatorial Natural Killer Cell-based Immunotherapy Approaches Selectively Target Chordoma Cancer Stem Cells.
Hoke ATK; Padget MR; Fabian KP; Nandal A; Gallia GL; Bilusic M; Soon-Shiong P; Hodge JW; London NR
Cancer Res Commun; 2021 Dec; 1(3):127-139. PubMed ID: 35765577
[TBL] [Abstract][Full Text] [Related]
7. The role of tumor immune microenvironment in chordoma: promising immunotherapy strategies.
Xu J; Shi Q; Wang B; Ji T; Guo W; Ren T; Tang X
Front Immunol; 2023; 14():1257254. PubMed ID: 37720221
[TBL] [Abstract][Full Text] [Related]
8. Challenges of local recurrence and cure in low grade malignant tumors of the spine.
Boriani S; Saravanja D; Yamada Y; Varga PP; Biagini R; Fisher CG
Spine (Phila Pa 1976); 2009 Oct; 34(22 Suppl):S48-57. PubMed ID: 19829277
[TBL] [Abstract][Full Text] [Related]
9. Acquired Immune Resistance Follows Complete Tumor Regression without Loss of Target Antigens or IFNγ Signaling.
Donia M; Harbst K; van Buuren M; Kvistborg P; Lindberg MF; Andersen R; Idorn M; Munir Ahmad S; Ellebæk E; Mueller A; Fagone P; Nicoletti F; Libra M; Lauss M; Hadrup SR; Schmidt H; Andersen MH; Thor Straten P; Nilsson JA; Schumacher TN; Seliger B; Jönsson G; Svane IM
Cancer Res; 2017 Sep; 77(17):4562-4566. PubMed ID: 28655789
[TBL] [Abstract][Full Text] [Related]
10. Advances in immune checkpoint inhibitors for bone sarcoma therapy.
Thanindratarn P; Dean DC; Nelson SD; Hornicek FJ; Duan Z
J Bone Oncol; 2019 Apr; 15():100221. PubMed ID: 30775238
[TBL] [Abstract][Full Text] [Related]
11. Predicting clinical outcomes in chordoma patients receiving immunotherapy: a comparison between volumetric segmentation and RECIST.
Fenerty KE; Folio LR; Patronas NJ; Marté JL; Gulley JL; Heery CR
BMC Cancer; 2016 Aug; 16(1):672. PubMed ID: 27553491
[TBL] [Abstract][Full Text] [Related]
12. Stereotactic Radiation Therapy Augments Antigen-Specific PD-1-Mediated Antitumor Immune Responses via Cross-Presentation of Tumor Antigen.
Sharabi AB; Nirschl CJ; Kochel CM; Nirschl TR; Francica BJ; Velarde E; Deweese TL; Drake CG
Cancer Immunol Res; 2015 Apr; 3(4):345-55. PubMed ID: 25527358
[TBL] [Abstract][Full Text] [Related]
13. Chordoma: A Case Report and Review of Literature.
Noor A; Bindal P; Ramirez M; Vredenburgh J
Am J Case Rep; 2020 Jan; 21():e918927. PubMed ID: 31969553
[TBL] [Abstract][Full Text] [Related]
14. The next step: innovative molecular targeted therapies for treatment of intracranial chordoma patients.
Barry JJ; Jian BJ; Sughrue ME; Kane AJ; Mills SA; Tihan T; Parsa AT
Neurosurgery; 2011 Jan; 68(1):231-40; discussion 240-1. PubMed ID: 21099719
[TBL] [Abstract][Full Text] [Related]
15. Medical treatment of advanced chordomas.
Colia V; Stacchiotti S
Eur J Cancer; 2017 Sep; 83():220-228. PubMed ID: 28750274
[TBL] [Abstract][Full Text] [Related]
16. Recent advances in understanding and managing chordomas: an update.
Connors SW; Aoun SG; Shi C; Peinado-Reyes V; Hall K; Bagley CA
F1000Res; 2020; 9():. PubMed ID: 32724558
[TBL] [Abstract][Full Text] [Related]
17. Chordoma: current concepts, management, and future directions.
Walcott BP; Nahed BV; Mohyeldin A; Coumans JV; Kahle KT; Ferreira MJ
Lancet Oncol; 2012 Feb; 13(2):e69-76. PubMed ID: 22300861
[TBL] [Abstract][Full Text] [Related]
18. Metastatic clival chordoma: a case report of multiple extraneural metastases following resection and proton beam radiotherapy in a 5-year old boy.
Rutkowski MJ; Birk HS; Wood MD; Perry A; Nicolaides T; Ames CP; Gupta N
J Neurosurg Pediatr; 2017 May; 19(5):531-537. PubMed ID: 28304223
[TBL] [Abstract][Full Text] [Related]
19. Best practices for the management of local-regional recurrent chordoma: a position paper by the Chordoma Global Consensus Group.
Stacchiotti S; Gronchi A; Fossati P; Akiyama T; Alapetite C; Baumann M; Blay JY; Bolle S; Boriani S; Bruzzi P; Capanna R; Caraceni A; Casadei R; Colia V; Debus J; Delaney T; Desai A; Dileo P; Dijkstra S; Doglietto F; Flanagan A; Froelich S; Gardner PA; Gelderblom H; Gokaslan ZL; Haas R; Heery C; Hindi N; Hohenberger P; Hornicek F; Imai R; Jeys L; Jones RL; Kasper B; Kawai A; Krengli M; Leithner A; Logowska I; Martin Broto J; Mazzatenta D; Morosi C; Nicolai P; Norum OJ; Patel S; Penel N; Picci P; Pilotti S; Radaelli S; Ricchini F; Rutkowski P; Scheipl S; Sen C; Tamborini E; Thornton KA; Timmermann B; Torri V; Tunn PU; Uhl M; Yamada Y; Weber DC; Vanel D; Varga PP; Vleggeert-Lankamp CLA; Casali PG; Sommer J
Ann Oncol; 2017 Jun; 28(6):1230-1242. PubMed ID: 28184416
[TBL] [Abstract][Full Text] [Related]
20. Understanding Tumor-Antigen Presentation in the New Era of Cancer Immunotherapy.
Cerezo-Wallis D; Soengas MS
Curr Pharm Des; 2016; 22(41):6234-6250. PubMed ID: 27568731
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
